These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21224537)

  • 1. [Our experience of the treatment with cetuximab for unresectable advanced colorectal cancer].
    Yokomizo H; Yoshimatsu K; Osawa G; Matsumoto A; Otani T; Yano Y; Itagaki H; Fujimoto T; Umehara A; Ogawa K
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2249-51. PubMed ID: 21224537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The efficacy of cetuximab for metastatic colorectal cancer].
    Katsumoto Y; Aritake N; Endoh A
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2523-5. PubMed ID: 21224627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
    Scartozzi M; Bearzi I; Pierantoni C; Mandolesi A; Loupakis F; Zaniboni A; Catalano V; Quadri A; Zorzi F; Berardi R; Biscotti T; Labianca R; Falcone A; Cascinu S
    J Clin Oncol; 2007 Sep; 25(25):3930-5. PubMed ID: 17761976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy].
    Yoda Y; Yoshino T; Kadowaki S; Bando H; Okano S; Fukushima H; Fuse N; Tahara M; Doi T; Ohtsu A
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):1003-6. PubMed ID: 19542725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
    N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
    Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatment options for colorectal cancer.
    Erlichman C; Sargent DJ
    N Engl J Med; 2004 Jul; 351(4):391-2. PubMed ID: 15269321
    [No Abstract]   [Full Text] [Related]  

  • 8. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
    Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
    Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L
    Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pulmonary embolism during palliative chemotherapy including cetuximab for metastatic colorectal cancer].
    Goto A; Suzuki K; Hasegawa Y; Sukawa Y; Fujii K; Nishimura S; Yonezawa K; Abe T; Shinomura Y
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):169-71. PubMed ID: 20087056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer: outcome study in clinical practice.
    Lelli G; Cataldo S; Carandina I; Urbini B; Bonetti F; Marzola M; Biasco G; Pantaleo MA; Brandes A; Calandri C; Ravaioli E; Nanni O; Boni C; Banzi C; Negri F; Panetta A; DI Fabio F; Turci D
    J Chemother; 2008 Jun; 20(3):374-9. PubMed ID: 18606595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
    Guo GF; Xia LP; Qiu HJ; Xu RH; Zhang B; Jiang WQ; Zhou FF; Wang F
    Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):777-81. PubMed ID: 21163071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab in colon cancer.
    Costa AF; Sander GB; Picon PD
    N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473024
    [No Abstract]   [Full Text] [Related]  

  • 14. Cetuximab in colon cancer.
    Martin MJ
    N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473023
    [No Abstract]   [Full Text] [Related]  

  • 15. [A case of multiple lung and liver metastases from colon cancer treated with clinical benefit by hepatic arterial infusion chemotherapy plus cetuximab mono-therapy after standard chemotherapy failure].
    Osawa G; Yoshimatsu K; Yokomizo H; Otani T; Yano Y; Itagaki H; Matsumoto A; Fujimoto T; Umehara A; Ogawa K
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2526-8. PubMed ID: 21224628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cetuximab in combination with chemotherapy for patients with gastrointestinal cancer].
    Zhang XT; Shen L; Zhang XD; Li J; Zhang ZT
    Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):385-8. PubMed ID: 18953842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities.
    Gamucci T; Nelli F; Cianci G; Grassi G; Moscetti L; Sperduti I; Zeuli M; Cortesi E; D'Auria G; Pollera CF
    Clin Colorectal Cancer; 2008 Jul; 7(4):273-9. PubMed ID: 18650196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hepatic resection after systemic chemotherapy for liver metastasis of colorectal cancer].
    Nishigaki T; Ide Y; Murata K
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2566-8. PubMed ID: 21224641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer.
    Bouchahda M; Macarulla T; Spano JP; Bachet JB; Lledo G; Andre T; Landi B; Tabernero J; Karaboué A; Domont J; Levi F; Rougier P
    Crit Rev Oncol Hematol; 2008 Sep; 67(3):255-62. PubMed ID: 18400508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
    Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
    J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.